Sponsor Dossier
Link Pharmaceuticals
Sponsor Dossier for Link Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACETYLCYSTEINE-LINK
- Brand: ADRENALINE-LINK
- Brand: ALACARE
- Brand: ALLMERCAP
- Brand: ATACAND
- Brand: CEENU
- Brand: CHLOROMYCETIN
- Brand: COLISTIN
- Device (sponsor): Medicine administration kit, oral
- Device (sponsor): Organ preservation solution
- Device (sponsor): Organ preservation solution
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): STuberculin-allergy syringe/retractable-needle
- Device (sponsor): Wet wipe
About
Link Pharmaceuticals is an Australian Private Company with ABN 73010971516, registered in NSW and currently active.
Portfolio
Link Pharmaceuticals has 30 brands on the ARTG, of which 29 are indexable and 25 carry a Product Information document. 11 brands are PBS-listed, 5 have a PBAC outcome on record, and 9 have an AusPAR on record. Notable brands include ACETYLCYSTEINE-LINK, ADRENALINE-LINK, ALACARE, ALLMERCAP, ATACAND, CEENU, CHLOROMYCETIN, COLISTIN, ETOPOPHOS, FAMPYRA, FETROJA, FOSCAVIR.
Therapeutic focus
— Oncology: 7 brands — Infectious Disease: 6 brands — Neurology: 5 brands — Cardiology: 3 brands — Haematology: 1 brand — Psychiatry: 1 brand — Musculoskeletal: 1 brand — Complementary Medicine: 1 brand — Dermatology: 1 brand — Gastroenterology: 1 brand — Immunology: 1 brand — Endocrinology: 1 brand — Hepatology: 1 brand
PBS footprint
11 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2023-09-01, across 5 brands with a PBAC outcome on record. The latest AusPAR is 2026-10-15, across 9 brands with an AusPAR on record.